MicroRNA-219 in the Central Nervous System: a Potential Theranostic Approach

Overview

Journal Res Pharm Sci

Date 2025 Feb 6

PMID 39911893

Authors

Nahal Shamaeizadeh

Mina Mirian

Affiliations

Soon will be listed here.

Abstract

Despite the recent therapeutic advances in neurological disorders, curative therapy remains a serious challenge in many cases. Even though recent years have witnessed the development of gene therapy from among the different therapeutic approaches affecting pathophysiological mechanisms, intriguing aspects exist regarding the effectiveness, safety, and mechanism of action of gene therapies. Micro ribonucleic acid (microRNA-miRNA), as a fundamental gene regulator, regulates messenger ribonucleic acid (mRNA) by directly binding through the 3'-untranslated region (3'-UTR). MicroRNA-219 is a specific brain-enriched miRNA associated with neurodevelopmental disorders that play crucial roles in the differentiation of oligodendrocyte progenitorcells, promotion of oligodendrocyte maturation, remyelination, and cognitive functions to the extent that it can be considered a potential therapeutic option for demyelination in multiple sclerosis and spinal cord injury and reverse chronic inflammation pains. Additionally, miR-219 regulates the circadian clock, influencing the duration of the circadian clock period. This regulation can impact mood stability and is associated with phase fluctuations in bipolar patients. Furthermore, miR-219 also plays a role in modulating tau toxicity, which is relevant to the pathophysiology of Alzheimer's disease and schizophrenia. Finally, it reportedly has protective effects against seizures and Parkinson's disease, as well as neoplasms, by inhibiting proliferation, suppressing invasion, and inducing cell death in tumor cells. Exploring the miR-219 molecular pathways and their therapeutic effects on central nervous system disorders and the mechanisms involved, the present review study aims to illustrate how this information may change the future of gene therapy.

References

Moreels M, Vandenabeele F, Dumont D, Robben J, Lambrichts I . Alpha-smooth muscle actin (alpha-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of transforming growth factor-beta 1 (TGF-beta1). Neuropathol Appl Neurobiol. 2007; 34(5):532-46. DOI: 10.1111/j.1365-2990.2007.00910.x. View

Martin L, Latypova X, Wilson C, Magnaudeix A, Perrin M, Yardin C . Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2012; 12(1):289-309. DOI: 10.1016/j.arr.2012.06.003. View

Pekny M, Pekna M . Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014; 94(4):1077-98. DOI: 10.1152/physrev.00041.2013. View

Kuss A, Chen W . MicroRNAs in brain function and disease. Curr Neurol Neurosci Rep. 2008; 8(3):190-7. DOI: 10.1007/s11910-008-0031-0. View

Zhao X, He X, Han X, Yu Y, Ye F, Chen Y . MicroRNA-mediated control of oligodendrocyte differentiation. Neuron. 2010; 65(5):612-26. PMC: 2855245. DOI: 10.1016/j.neuron.2010.02.018. View

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

Darzi L, Boshtam M, Shariati L, Kouhpayeh S, Gheibi A, Mirian M . The silencing effect of miR-30a on gene expression : an approach for gene therapy. Res Pharm Sci. 2017; 12(6):456-464. PMC: 5691572. DOI: 10.4103/1735-5362.217426. View

Zhang S, Rasai A, Wang Y, Xu J, Bannerman P, Erol D . The Stem Cell Factor Sox2 Is a Positive Timer of Oligodendrocyte Development in the Postnatal Murine Spinal Cord. Mol Neurobiol. 2018; 55(12):9001-9015. PMC: 6173662. DOI: 10.1007/s12035-018-1035-7. View

Ebrahimi-Barough S, Kouchesfehani H, Ai J, Mahmoodinia M, Tavakol S, Massumi M . Programming of human endometrial-derived stromal cells (EnSCs) into pre-oligodendrocyte cells by overexpression of miR-219. Neurosci Lett. 2013; 537:65-70. DOI: 10.1016/j.neulet.2013.01.022. View

10.

Cermakian N, Reppert S, Sassone-Corsi P . Bimodal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity. Proc Natl Acad Sci U S A. 2002; 99(11):7728-33. PMC: 124335. DOI: 10.1073/pnas.102075599. View

11.

Santa-Maria I, Alaniz M, Renwick N, Cela C, Fulga T, Van Vactor D . Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest. 2015; 125(2):681-6. PMC: 4319412. DOI: 10.1172/JCI78421. View

12.

Murai K, Qu Q, Sun G, Ye P, Li W, Asuelime G . Nuclear receptor TLX stimulates hippocampal neurogenesis and enhances learning and memory in a transgenic mouse model. Proc Natl Acad Sci U S A. 2014; 111(25):9115-20. PMC: 4078800. DOI: 10.1073/pnas.1406779111. View

13.

Hass J, Walton E, Wright C, Beyer A, Scholz M, Turner J . Associations between DNA methylation and schizophrenia-related intermediate phenotypes - a gene set enrichment analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2015; 59:31-39. PMC: 4346504. DOI: 10.1016/j.pnpbp.2015.01.006. View

14.

Nelson P, Wang W, Rajeev B . MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008; 18(1):130-8. PMC: 2859437. DOI: 10.1111/j.1750-3639.2007.00120.x. View

15.

Gugliandolo A, Chiricosta L, Boccardi V, Mecocci P, Bramanti P, Mazzon E . MicroRNAs Modulate the Pathogenesis of Alzheimer's Disease: An In Silico Analysis in the Human Brain. Genes (Basel). 2020; 11(9). PMC: 7564652. DOI: 10.3390/genes11090983. View

16.

Cheng H, Papp J, Varlamova O, Dziema H, Russell B, Curfman J . microRNA modulation of circadian-clock period and entrainment. Neuron. 2007; 54(5):813-29. PMC: 2590749. DOI: 10.1016/j.neuron.2007.05.017. View

17.

Crespo-Biel N, Theunis C, Van Leuven F . Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis. 2012; 2012:251426. PMC: 3376502. DOI: 10.1155/2012/251426. View

18.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

19.

Balan S, Toyoshima M, Yoshikawa T . Contribution of induced pluripotent stem cell technologies to the understanding of cellular phenotypes in schizophrenia. Neurobiol Dis. 2018; 131:104162. DOI: 10.1016/j.nbd.2018.04.021. View

20.

Wang H, Moyano A, Ma Z, Deng Y, Lin Y, Zhao C . miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS. Dev Cell. 2017; 40(6):566-582.e5. PMC: 5569304. DOI: 10.1016/j.devcel.2017.03.001. View